Infographic: Biosimilar Trastuzumab

Data from 5 studies presented at the European Society for Medical Oncology (ESMO) 2017 meeting highlighted the progress of biosimilar trastuzumab candidates.

Related Content:

Oncology

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

Denosumab, Golimumab Biosimilars Clear Major Regulatory Milestones in Europe, as US Hurdles Remain

Medicare Modeling Shows Major Savings With Biosimilar Bevacizumab Use